CASTLE BIOSCIENCES INC — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Castle Biosciences reported Q2 2026 revenue of $103.5M (vs. $86.2M in Q2 2025), with core revenue drivers (DecisionDx-Melanoma and TissueCypher) increasing 32% year-over-year. The company raised full-year 2026 revenue guidance from $345-355M to $365-375M and expects to achieve positive Adjusted EBITDA in Q3, Q4, and full-year 2026. Cash position stands at $266.8M as of June 30, 2026.
Why this rating
Guidance raise of ~$20M midpoint (5.8% increase) is meaningful relative to ~$576M market cap (~3.5%). Strong test volume growth and path to Adjusted EBITDA positivity are operationally significant, though near-term GAAP profitability remains distant.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.